05:43 PM EST, 12/09/2024 (MT Newswires) -- Biomea Fusion ( BMEA ) said late Monday that preliminary data from an ongoing phase I study of BMF-500 supports its potential as a transformative therapy for patients with FMS-like tyrosine kinase 3 mutated relapsed or refractory acute leukemia, a type of cancer. The investigational therapy demonstrated a favorable safety and tolerability profile...

05:44 PM EST, 12/09/2024 (MT Newswires) -- Nanobiotix ( NBTX ) said late Monday it completed the dose escalation and expansion phases of a phase 1 study evaluating radiotherapy-activated NBTXR3 for patients with advanced or borderline resectable pancreatic cancer. The study showed promising results, with a 23-month median overall survival from diagnosis in 22 patients, compared to a 19.2-month historical...

05:41 PM EST, 12/09/2024 (MT Newswires) -- Fate Therapeutics ( FATE ) said new data from FT819's phase 1 study in patients with moderate to severe systemic lupus erythematosus showed no dose-limiting toxicities in the first three patients. The drug showed rapid, deep and sustained depletion of CD19+ B cells in the periphery and a favorable safety profile, the company...

05:43 PM EST, 12/09/2024 (MT Newswires) -- Invesco ( IVZ ) reported preliminary assets under management late Monday of $1.857 trillion at the end of November, up 4.8% month over month. The company said favorable market returns positively affected AUM by $52 billion and foreign exchange decreased it by $3 billion, respectively. ...